O'Neill Sheila, MacLennan Alastair, Bass Shona, Diamond Terry, Ebeling Peter, Findlay David, Flicker Leon, Markwell Alex, Nowson Caryl, Pocock Nick, Sambrook Philip, Singh Maria Fiatarone
Betty Byrne Henderson Women's Health Research Centre, Royal Brisbane and Women's Hospital, Queensland.
Aust Fam Physician. 2004 Nov;33(11):910-9.
Since the last series of guidelines on the management of osteoporosis from Osteoporosis Australia was published in Australian Family Physician (October 2002), there have been further advances in our understanding of the treatment involved in both the prevention of bone loss and the management of established osteoporosis.
This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies.
Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.
自澳大利亚骨质疏松协会上一系列骨质疏松管理指南于《澳大利亚家庭医生》(2002年10月)发表以来,我们对预防骨质流失和治疗已确诊骨质疏松症所涉及的治疗方法有了进一步认识。
本文提供绝经后骨质疏松症管理的最新指南,以帮助全科医生识别有风险的女性,并回顾当前的治疗策略。
骨质疏松症及其相关问题是澳大利亚主要的健康问题,尤其是在人口老龄化的情况下。虽然管理的重要原则仍然被认为是最大化峰值骨量和预防绝经后骨质流失,但关于双膦酸盐、雷洛昔芬和雌激素等药物的新临床试验数据最近已经可得,各种药物的相对作用也逐渐变得更加清晰。长期激素治疗的风险和益处参差不齐,需要对个体患者进行咨询。